Workshops Day One
Day one: Monday 7th November 2016
workshops day one
Dr Kassim Javaid
Hon Consultant in Metabolic Bone Disease, University of Oxford
Fracture Liaison Service models including non-hip fracture database: Hall 10b
- What are the key methods for case finding?
- What are the key assessment / investigations to recommend?
- How should I monitor patients?
Delivering effective secondary fracture prevention is challenging and requires coordination between hospitals and community services. Different FLS model systems have evolved to deliver the key components of an effective service. The aim of the workshop is to allow attendees to understand the strengths and weakness of these models and use this information to develop new services or improve existing ones.
Professor Opinder Sahota
Consultant Care of the Elderly, QMC, Nottingham
Management of individuals with symptomatic vertebral fracture: Hall 10a
- What investigations should I undertake in patients with a vertebral fracture?
- How should I manage a patient with an acute vertebral fracture?
- What is the difference between vertebroplasty and kyphoplasty?
Vertebral fragility fractures (VFFs) are common - and can be associated with acute severe back pain. Traditionally, these are managed conservatively: however, over the past few years there has been a shift towards active management, with the use of vertebral augmentation. The aim of the workshop is to present a treatment pathway for the management of acute VFFs and sacral insufficiency fractures.
Professor Richard Eastell
Professor of Bone Metabolism, University of Sheffield. Director of the Mellanby Centre for Bone Research, Sheffield, UK
Screening for secondary osteoporosis: Hall 11a
- Who should have laboratory testing for secondary osteoporosis?
- What tests should be included initially?
- What actions should we take when these tests are abnormal?
Osteoporosis may be a sign of underlying disease. Such diseases can often be identified on careful questioning or by administering a standard questionnaire. However, other diseases require laboratory investigation and these include coeliac disease, hyperthyroidism and idiopathic hypercalciuria. The workshop will propose an approach to laboratory testing and interpretation of the results.
Dr Ken Poole
Senior Lecturer; Honorary Consultant in Metabolic Bone Disease and Rheumatology, Department of Medicine, University of Cambridge
Managing osteoporosis in disabling conditions: Hall 6b
- What fractures occur in patients with immobility and chronic disabling illnesses?
- What treatment options are there to prevent fractures in disabling illnesses?
- What are the particular considerations when diagnosing bone fragility in children and adults with disabling illnesses?
Osteoporosis and fragility fractures can add to the misery of chronic disabling illness in adults and children. Unlike common osteoporotic fractures, individuals with disability tend to break different bones with distinct mechanisms. Also, extra care is needed when selecting standard osteoporosis drugs for prevention and treatment of bone loss in these individuals. In this workshop, Ken will illustrate several diagnostic and treatment conundrums by studying real adult and paediatric cases and their management.
Commissioning Advisor, National Osteoporosis Society
Let’s make it better! A practical look at the “science” of service improvement: Executive One
- What are the main obstacles to improving services for patients and how can I overcome these?
- Are there lessons I can learn from my own attempts to improve services?
- What tools and techniques will help me to make it happen?
We all want to make things better for patients but so much gets in the way. Improving services takes determination and skill, and this practical workshop draws on evidence, case studies and examples of where success has been achieved. Tim Jones is a service improvement lead at the National Osteoporosis Society and has worked with dozens of sites. Material is drawn from fracture prevention projects but the lessons can be applied to any situation.
Lead Nurse Falls and Fractures, Falls and Fracture Programme Lead - Birmingham Public Health
Quality improvement of osteoporosis and Fracture Liaison Services: Executive Two
- How do I apply the NOS FLS standards to an FLS in an acute setting?
- How do I capture and measure patient experience of an FLS?
- How do I integrate falls prevention in an FLS?
Delivering a modern FLS is often a challenge. The NOS has provided a set of standards against which we can measure the quality of the service we deliver. Often and traditionally, falls and fracture services are seen as being delivered by different services. The aim of the workshop is to present a model that demonstrates that it is possible to deliver the NOS standards, report against these to the commissioners and capture patient experience to make sure we are delivering a patient-centred approach.
Dr Tehseen Ahmed
Consultant Rheumatologist, Royal National Hospital for Rheumatic Diseases, Bath
How to interpret serial DXA measurements: Hall 11b
- What is meant by the terms “precision assessment”, “precision error”, and “least significant change”?
- How is the least significant change calculated?
- How can I use knowledge of the least significant change to inform patient management?
Do you perform or interpret DXA scans? If so, this workshop is relevant to you. We aim to help you follow best practice when it comes to performing and analysing DXA scans. There will be a particular emphasis on the concepts of precision error and least significant change. A thorough understanding of these concepts is vital when interpreting serial changes in bone density and will impact management of your patients.
Professor Eugene McCloskey
Professor of Adult Bone Diseases, Sheffield Director of MRC-Arthritis Research UK Centre for Integrated research in Musculoskeletal Ageing
Cancer and bone: Hall 6a
- Which patients with breast cancer should get routine bisphosphonate therapy to prevent bone metastases?
- Which bisphosphonate should I use?
- How and when should I act to prevent cancer-treatment-induced bone loss?
Significant advances in our knowledge of the interaction between cancer and bone are leading to step changes in the management of patients with early and advanced disease. The prevention of bone metastases in postmenopausal women with breast cancer is now an established role for bisphosphonates. The impact of cancer therapies on bone loss, particularly those affecting on gonadal or hormonal function, and the ability of bone therapies to prevent such loss and decrease fracture risk are also becoming well established.